Literature DB >> 29445927

Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion.

Kambiz Rahbar1, Matthias Weckesser2, Hojjat Ahmadzadehfar3, Michael Schäfers2, Lars Stegger2, Martin Bögemann4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29445927     DOI： 10.1007/s00259-018-3952-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  2 in total

1.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Authors:  Ali Afshar-Oromieh; Tim Holland-Letz; Frederik L Giesel; Clemens Kratochwil; Walter Mier; Sabine Haufe; Nils Debus; Matthias Eder; Michael Eisenhut; Martin Schäfer; Oliver Neels; Markus Hohenfellner; Klaus Kopka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-12       Impact factor: 9.236

2.  F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.

Authors:  Frederik L Giesel; B Hadaschik; J Cardinale; J Radtke; M Vinsensia; W Lehnert; C Kesch; Y Tolstov; S Singer; N Grabe; S Duensing; M Schäfer; O C Neels; W Mier; U Haberkorn; K Kopka; C Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-26       Impact factor: 9.236
  2 in total
  26 in total

1.  18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics.

Authors:  Kambiz Rahbar; Ali Afshar-Oromieh; Martin Bögemann; Stefan Wagner; Michael Schäfers; Lars Stegger; Matthias Weckesser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-14       Impact factor: 9.236

Review 2.  [Hybrid imaging in prostate cancer : Status quo and future applications].

Authors:  Michal-Kamil Chodyla; Matthias Eiber; Axel Wetter; Isabel Rauscher
Journal:  Radiologe       Date:  2020-05       Impact factor: 0.635

3.  Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.

Authors:  Christian Uprimny; Steffen Bayerschmidt; Alexander Stephan Kroiss; Josef Fritz; Bernhard Nilica; Hanna Svirydenka; Clemens Decristoforo; Elisabeth von Guggenberg; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  J Nucl Med       Date:  2021-03-12       Impact factor: 10.057

4.  Prostate cancer GTV delineation with biparametric MRI and 68Ga-PSMA-PET: comparison of expert contours and semi-automated methods.

Authors:  Nathan Hearn; John Blazak; Philip Vivian; Dinesh Vignarajah; Katelyn Cahill; Daisy Atwell; Jim Lagopoulos; Myo Min
Journal:  Br J Radiol       Date:  2021-01-28       Impact factor: 3.039

5.  Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy.

Authors:  Isabel Rauscher; Markus Krönke; Michael König; Andrei Gafita; Tobias Maurer; Thomas Horn; Kilian Schiller; Wolfgang Weber; Matthias Eiber
Journal:  J Nucl Med       Date:  2019-06-28       Impact factor: 11.082

6.  Detection efficacy of 18F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.

Authors:  Isabel Rauscher; Amir Karimzadeh; Kilian Schiller; Thomas Horn; Calogero D'Alessandria; Charlott Franz; Hannah Wörther; Noemi Nguyen; Stephanie E Combs; Wolfgang Andreas Weber; Matthias Eiber
Journal:  J Nucl Med       Date:  2021-03-12       Impact factor: 11.082

7.  Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer.

Authors:  Kambiz Rahbar; Ali Afshar-Oromieh; Robert Seifert; Stefan Wagner; Michael Schäfers; Martin Bögemann; Matthias Weckesser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-20       Impact factor: 9.236

8.  Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.

Authors:  Frederik L Giesel; Karina Knorr; Fabian Spohn; Leon Will; Tobias Maurer; Paul Flechsig; Oliver Neels; Kilian Schiller; Horacio Amaral; Wolfgang A Weber; Uwe Haberkorn; Markus Schwaiger; Clemens Kratochwil; Peter Choyke; Vasko Kramer; Klaus Kopka; Matthias Eiber
Journal:  J Nucl Med       Date:  2018-07-24       Impact factor: 10.057

Review 9.  18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.

Authors:  Rudolf A Werner; Thorsten Derlin; Constantin Lapa; Sara Sheikbahaei; Takahiro Higuchi; Frederik L Giesel; Spencer Behr; Alexander Drzezga; Hiroyuki Kimura; Andreas K Buck; Frank M Bengel; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

10.  The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis.

Authors:  Rang Wang; Guohua Shen; Mingxing Huang; Rong Tian
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.